Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Shared management of patients with concomitant rheumatological disease and neoplasia: A collaborative Delphi consensus by the Italian Association of Medical Oncology and the Italian Society of Rheumatology.

Created on 10 Nov 2026

Authors

Luigi De Marco, Michelina Turri, Antonio Carletto, Fulvia Ceccarelli, Francesco Ciccia, Lorenzo Dagna, Ginevra De Marchi, Ennio Giulio Favalli, Alessandro Inno, Giuseppe Lopalco, Ennio Lubrano, Luca Quartuccio, Immacolata Prevete, Roberta Ramonda, Nicola Silvestris, Marcello Tiseo, Andrea Doria, Francesco Perrone, Augusta Ortolan, Maria Sole Chimenti, “Rheumatologic-Oncologic Multidisciplinary Assessment - Rh.O.M.A.” SIR Study Group

Published in

Autoimmunity reviews. Pages 104228. Nov 09, 2026. Epub Nov 09, 2026.

Abstract

The increasing intersection between rheumatological and oncological diseases-particularly in the context of immunostimulatory cancer therapies-poses significant clinical challenges. Immunotherapy may induce new-onset autoimmune or rheumatologic manifestations, while immunosuppressive anti-rheumatic therapies may impact cancer risk and outcomes. However, solid epidemiological data and guidelines on how to manage such scenarios are lacking. This project aimed to develop expert-based guidance to support decision-making in patients with concurrent rheumatological and oncological disease or immune-related adverse events due to oncological therapies.
A modified Delphi process was conducted based on anonymity, iterative feedback, and multidisciplinary involvement. After a narrative review (54 articles, 2000-2025), three key assumptions and two sets of consensus statements were developed: Section A (7 statements) and Section B (4 statements). An expert panel of 18 clinicians (14 rheumatologists and 4 oncologists), supported by 2 methodologists, rated each statement on a 1-10 scale. Rated each statement on a 1-10 scale. Statements with lower agreement were revised and re-evaluated in in one or more additional rounds.. Voting was anonymous. Agreement was defined as >70% of experts rating a statement ≥7.5.
All statements reached consensus, in most cases after two rounds, and one (A4) after a third round following a substantial re-formulation.. One assumption was eliminated and three statements revised. Final agreement was reached on two assumptions and 11 statements. Experts emphasized individualized cancer risk assessment in patients on csDMARDs or bDMARDs, and early rheumatological evaluation in cancer patients with immune-related adverse events. Though robust cause-effect data are lacking, expert clinical experience may support preliminary recommendations.
This consensus provides structured, clinically grounded guidance for managing key challenges at the intersection of oncology and rheumatology.

PMID:
43003172
Bibliographic data and abstract were imported from PubMed on 10 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 48
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement